Last reviewed · How we verify
Desvenlafaxine succinate 100mg
Desvenlafaxine succinate 100mg, marketed by Seoul National University Hospital, is a serotonin-norepinephrine reuptake inhibitor (SNRI) currently available in the market. The key composition patent for this drug is set to expire in 2028, providing a period of exclusivity that supports its market position. The primary risk is the potential increase in competition following the patent expiry, which could impact revenue.
At a glance
| Generic name | Desvenlafaxine succinate 100mg |
|---|---|
| Sponsor | Seoul National University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression (PHASE2)
- Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy (PHASE3)
- Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Pre- and Post-Desvenlafaxine Treatment (PHASE4)
- Desvenlafaxine in Opioid-Dependent Patients (PHASE4)
- Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen (PHASE4)
- 12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder (PHASE4)
- Desvenlafaxine Monotherapy in Dysthymia (NA)
- A Study of Sustained-Release Desvenlafaxine Hydrochloride for the Treatment of Major Depressive Disorder (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Desvenlafaxine succinate 100mg CI brief — competitive landscape report
- Desvenlafaxine succinate 100mg updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI